132 related articles for article (PubMed ID: 36687427)
1. Severe hypoglycemia in patients with liver cirrhosis and type 2 diabetes.
Yen FS; Hou MC; Liu JS; Hsu CC; Hwu CM
Front Med (Lausanne); 2022; 9():962337. PubMed ID: 36687427
[TBL] [Abstract][Full Text] [Related]
2. Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?
Yen FS; Lai JN; Wei JC; Chiu LT; Hsu CC; Hou MC; Hwu CM
BMC Gastroenterol; 2021 Jun; 21(1):263. PubMed ID: 34118892
[TBL] [Abstract][Full Text] [Related]
3. Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis.
Yen FS; Huang YH; Hou MC; Hwu CM; Lo YR; Shin SJ; Hsu CC
Br J Clin Pharmacol; 2022 Jan; 88(1):311-322. PubMed ID: 34198358
[TBL] [Abstract][Full Text] [Related]
4. The Risk of Severe Hypoglycemia and Mortality in Patients With Type 2 Diabetes and Discharged With Acute Liver Injury.
Yen FS; Hou MC; Pan CW; Liu JS; Hsu CC; Hwu CM
Diabetes Care; 2023 Jan; 46(1):20-27. PubMed ID: 36378550
[TBL] [Abstract][Full Text] [Related]
5. Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis.
Yen FS; Lai JN; Wei JC; Chiu LT; Hwu CM; Hou MC; Hsu CC
PLoS One; 2020; 15(12):e0243783. PubMed ID: 33315940
[TBL] [Abstract][Full Text] [Related]
6. Liver-related long-term outcomes of alpha-glucosidase inhibitors in patients with diabetes and liver cirrhosis.
Yen FS; Hou MC; Wei JC; Shih YH; Hsu CY; Hsu CC; Hwu CM
Front Pharmacol; 2022; 13():1049094. PubMed ID: 36618937
[No Abstract] [Full Text] [Related]
7. Respiratory Outcomes of Insulin Use in Patients with COPD: A Nationwide Population-Based Cohort Study.
Yen FS; Chang SH; Wei JC; Shih YH; Hwu CM
Pharmaceuticals (Basel); 2023 Apr; 16(5):. PubMed ID: 37242426
[TBL] [Abstract][Full Text] [Related]
8. Thiazolidinediones were associated with higher risk of cardiovascular events in patients with type 2 diabetes and cirrhosis.
Yen FS; Wei JC; Chiu LT; Hsu CC; Hou MC; Hwu CM
Liver Int; 2021 Jan; 41(1):110-122. PubMed ID: 33124143
[TBL] [Abstract][Full Text] [Related]
9. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan.
Yen FS; Wei JC; Yip HT; Hwu CM; Hou MC; Hsu CC
Hepatol Int; 2021 Feb; 15(1):179-190. PubMed ID: 33423239
[TBL] [Abstract][Full Text] [Related]
11. Severe hypoglycemia and hip fracture in patients with type 2 diabetes: a nationwide population-based cohort study.
Hung YC; Lin CC; Chen HJ; Chang MP; Huang KC; Chen YH; Chen CC
Osteoporos Int; 2017 Jul; 28(7):2053-2060. PubMed ID: 28374044
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Severe Hypoglycemia Among Adults With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
Lee JY; Kim YE; Han K; Han E; Lee BW; Kang ES; Cha BS; Ko SH; Lee YH
JAMA Netw Open; 2022 Feb; 5(2):e220262. PubMed ID: 35195697
[TBL] [Abstract][Full Text] [Related]
13. Hypoglycemia-Related Hospitalizations and Mortality Among Patients With Diabetes Transitioning to Dialysis.
Rhee CM; Kovesdy CP; You AS; Sim JJ; Soohoo M; Streja E; Molnar MZ; Amin AN; Abbott K; Nguyen DV; Kalantar-Zadeh K
Am J Kidney Dis; 2018 Nov; 72(5):701-710. PubMed ID: 30037725
[TBL] [Abstract][Full Text] [Related]
14. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ
Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
[TBL] [Abstract][Full Text] [Related]
15. Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes.
Yen FS; Yang YC; Hwu CM; Wei JC; Huang YH; Hou MC; Hsu CC
Liver Int; 2020 May; 40(5):1089-1097. PubMed ID: 31960563
[TBL] [Abstract][Full Text] [Related]
16. Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality.
Eriksson JW; Bodegard J; Nathanson D; Thuresson M; Nyström T; Norhammar A
Diabetes Res Clin Pract; 2016 Jul; 117():39-47. PubMed ID: 27329021
[TBL] [Abstract][Full Text] [Related]
17. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
18. Severe hypoglycemia is associated with antidiabetic oral treatment compared with insulin analogs in nursing home patients with type 2 diabetes and dementia: results from the DIMORA study.
Abbatecola AM; Bo M; Barbagallo M; Incalzi RA; Pilotto A; Bellelli G; Maggi S; Paolisso G;
J Am Med Dir Assoc; 2015 Apr; 16(4):349.e7-12. PubMed ID: 25669671
[TBL] [Abstract][Full Text] [Related]
19. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia.
Yu O; Azoulay L; Yin H; Filion KB; Suissa S
Am J Med; 2018 Mar; 131(3):317.e11-317.e22. PubMed ID: 29032229
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes.
Min JY; Griffin MR; Hung AM; Grijalva CG; Greevy RA; Liu X; Elasy T; Roumie CL
J Gen Intern Med; 2016 Jun; 31(6):638-46. PubMed ID: 26921160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
